# EDGAR Filing Document

**Accession Number:** 0001863006
**File Stem:** 0001213900-26-055459
**Filing Date:** 2026-5
**Character Count:** 55591
**Document Hash:** ad277e1159670e8d3f39971d74db6084
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-055459.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001213900-26-055459

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 69

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Valens Semiconductor Ltd.
- **CENTRAL INDEX KEY:** 0001863006
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40842
- **FILM NUMBER:** 26970994

**BUSINESS ADDRESS:**
- **STREET 1:** 8 HANAGAR ST. POB 7152
- **CITY:** HOD HASHARON, 4501309
- **STATE:** L3
- **ZIP:** 00000
- **BUSINESS PHONE:** 972-9-762-6900

**MAIL ADDRESS:**
- **STREET 1:** 8 HANAGAR ST. POB 7152
- **CITY:** HOD HASHARON, 4501309
- **STATE:** L3
- **ZIP:** 00000

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2026

**Commission File Number: 001-40842**

**VALENS SEMICONDUCTOR LTD.**

**(Exact name of registrant as specified in its charter)**

**8 Hanagar St. POB 7152**

**Hod Hasharon 4501309**

**Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

Exhibit 99.1 to this report, furnished on Form 6-K, is incorporated by reference into the Registrant's registration statements on [Form F-3](https://www.sec.gov/Archives/edgar/data/1863006/000119312522258899/d316528dposam.htm) (File No. 333-260390) and Form S-8 (File Nos. [333-259849](https://www.sec.gov/Archives/edgar/data/1863006/000095010321014787/dp158559_s8.htm), [333-269250](https://www.sec.gov/Archives/edgar/data/1863006/000121390023002926/ea171494-s8_valenssemi.htm), [333-276520](https://www.sec.gov/Archives/edgar/data/1863006/000095010324000695/dp205272_s8.htm), [333-285792](https://www.sec.gov/Archives/edgar/data/1863006/000095010325003411/dp226190_s8.htm), and [333-293747](https://www.sec.gov/Archives/edgar/data/1863006/000121390026020403/ea0277982-s8_valens.htm)).

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **ITEM** |  |
| 99.1 | [Condensed Consolidated Financial Statements (Unaudited) as of and for the three months ended March 31, 2026](ea029011501ex99-1.htm) |
| 101.INS | Inline XBRL Instance Document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **VALENS SEMICONDUCTOR LTD.** | **VALENS SEMICONDUCTOR LTD.** | **VALENS SEMICONDUCTOR LTD.** |
| By: | /s/ Yoram Salinger | /s/ Yoram Salinger |
|  | Name: | Yoram Salinger |
|  | Title: | Chief Executive Officer |

---

Date: May 13, 2026

## Exhibit 99.1

?xml version='1.0' encoding='ASCII'?

**Exhibit 99.1**

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

MARCH 31, 2026

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

As of March 31, 2026

**CONTENTS**

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**Page** |
| **CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** (Unaudited) -**IN U.S. DOLLARS ($):** |  |
| &nbsp;&nbsp;&nbsp;[Balance sheets](#a_001) | &nbsp;&nbsp;F-3 - F-4 |
| &nbsp;&nbsp;&nbsp;[Statements of operations and comprehensive loss](#a_002) | &nbsp;&nbsp;F-5 |
| &nbsp;&nbsp;&nbsp;[Statements of changes in shareholder's equity](#a_003) | &nbsp;&nbsp;F_6 |
| &nbsp;&nbsp;&nbsp;[Statements of cash flows](#a_004) | &nbsp;&nbsp;F-7 |
| &nbsp;&nbsp;&nbsp;[Notes to consolidated financial statements](#a_005) | &nbsp;&nbsp;F-8 - F- 21 |

---

![](ea029011501_ex99-1img1.jpg)

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(U.S. dollars in thousands, except for number of shares and par value)

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| **Assets** | | |
| **CURRENT ASSETS:** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | 28970 | 27863 |
| &nbsp;&nbsp;&nbsp;Short-term deposits | 57147 | 64733 |
| &nbsp;&nbsp;&nbsp;Restricted short-term deposit | 1144 | 1132 |
| &nbsp;&nbsp;&nbsp;Trade accounts receivable | 10475 | 9971 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 4316 | 4842 |
| &nbsp;&nbsp;&nbsp;Inventories | 10906 | 10117 |
| **TOTAL CURRENT ASSETS** | 112958 | 118658 |
| **LONG-TERM ASSETS:** |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 2776 | 2901 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 6645 | 6901 |
| &nbsp;&nbsp;&nbsp;Intangible assets | 3526 | 3762 |
| &nbsp;&nbsp;&nbsp;Goodwill | 1847 | 1847 |
| &nbsp;&nbsp;&nbsp;Other assets | 668 | 632 |
| **TOTAL LONG-TERM ASSETS** | 15462 | 16043 |
| **TOTAL ASSETS** | 128420 | 134701 |

---

**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements**

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED BALANCE SHEETS (continued) (Unaudited)

(U.S. dollars in thousands, except for number of shares and par value)

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| **Liabilities and Shareholders' Equity** | | |
| **CURRENT LIABILITIES:** | | |
| &nbsp;&nbsp;&nbsp;Trade accounts payable | 4447 | 4698 |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 7767 | 7298 |
| &nbsp;&nbsp;&nbsp;Earnout liability | - | 282 |
| &nbsp;&nbsp;&nbsp;Current maturities of operating leases liabilities | 1587 | 1526 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 7878 | 9130 |
| **TOTAL CURRENT LIABILITIES** | 21679 | 22934 |
| **LONG-TERM LIABILITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Non-current operating leases liabilities | 6390 | 6717 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 111 | 67 |
| **TOTAL LONG-TERM LIABILITIES** | 6501 | 6784 |
| **TOTAL LIABILITIES** | 28180 | 29718 |
| **COMMITMENTS AND CONTINGENT LIABILITIES (note 4)** |  |  |
| **SHAREHOLDERS' EQUITY:** |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares, no par value: 700,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 105,722,413 and 106,352,460 shares issued and 105,722,413 and 103,050,266 shares outstanding as of March 31, 2026 and December 31, 2025, respectively | 49 | 49 |
| &nbsp;&nbsp;&nbsp;Treasury shares at cost: 0 and 3,302,194 shares as of March 31, 2026 and December 31, 2025, respectively | - | (10006) |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 353918 | 360013 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 65 | 429 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (253792) | (245502) |
| **TOTAL SHAREHOLDERS' EQUITY** | 100240 | 104983 |
| **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | 128420 | 134701 |

---

**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements**

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

(U.S. dollars in thousands, except share and per share amounts)

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2025** |
| **REVENUES** | 16859 | 16828 |
| **COST OF REVENUES** | (6372) | (6246) |
| **GROSS PROFIT** | 10487 | 10582 |
| **OPERATING EXPENSES:** |  |  |
| &nbsp;&nbsp;&nbsp;Research and development expenses | (10294) | (10590) |
| &nbsp;&nbsp;&nbsp;Sales and marketing expenses | (5396) | (5607) |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | (4017) | (3667) |
| &nbsp;&nbsp;&nbsp;Change in earnout liability | 282 | (174) |
| **TOTAL OPERATING EXPENSES** | (19425) | (20038) |
| **OPERATING LOSS** | (8938) | (9456) |
| **FINANCIAL INCOME, NET** | 673 | 1238 |
| **LOSS BEFORE INCOME TAXES** | (8265) | (8218) |
| **INCOME TAXES** | (27) | (93) |
| **LOSS AFTER INCOME TAXES** | (8292) | (8311) |
| Equity in earnings of investee | 2 | 3 |
| **NET LOSS** | **(8290)** | **(8308)** |
| **Basic and diluted net loss per ordinary share** | (0.08) | (0.08) |
| **Weighted average number of shares and vested RSUs used in computing net loss per ordinary share** | **105047377** | **105255959** |
| Other comprehensive loss: |  |  |
| Change in unrealized losses on cash flow hedges | (364) | (542) |
| **TOTAL COMPREHENSIVE LOSS** | **(8654)** | **(8850)** |

---

**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements**

**VALENS SEMICONDUCTOR LTD.**

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)

(U.S. dollars in thousands, except share data)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
|  | **Ordinary shares** | **Ordinary shares** | | | | | |
|  | **Shares** | **Amount** | **Additional<br> paid-**<br>**in capital** | **Treasury**<br>**Shares** | **Accumulated<br> other<br> comprehensive**<br>**income** | **Accumulated**<br>**Deficit** |<br>Total |
| **Balance as of January 1, 2026** | 103050266 | 49 | 360013 | (10006) | 429 | (245502) | 104983 |
| &nbsp;&nbsp;&nbsp;Exercise of options and vesting of RSUs | 2672147 | - | 775 |  | - | - | 775 |
| &nbsp;&nbsp;&nbsp;Retirement of treasury shares |  | - | (10006) | 10006 | - | - | - |
| &nbsp;&nbsp;&nbsp;Stock based compensation |  | - | 3136 |  | - | - | 3136 |
| &nbsp;&nbsp;&nbsp;Change in unrealized losses on cash flow hedges |  | - | - |  | (364) | - | (364) |
| &nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | - | - | (8290) | (8290) |
| **Balance as of March 31, 2026** | **105722413** | **49** | **353918** | **-**  | **65** | **(253792)** | **100240** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
|  | **Ordinary shares** | **Ordinary shares** | | | | | |
|  | **Shares** | **Amount** | **Additional<br> paid-**<br>**in capital** | **Treasury**<br>**Shares** | **Accumulated<br> other<br> comprehensive**<br>**income** | **Accumulated**<br>**Deficit** |<br>**Total** |
| **Balance as of January 1, 2025** | (\*)106,342,415 | 49 | 357570 | (1613) | 601 | (213919) | 142688 |
| &nbsp;&nbsp;&nbsp;Exercise of options and vesting of RSUs | 1780391 | - | 188 |  | - | - | 188 |
| &nbsp;&nbsp;&nbsp;Repurchase of ordinary shares | (3230259) | - | - | (9585) | - | - | (9585) |
| &nbsp;&nbsp;&nbsp;Stock based compensation |  | - | 4166 |  | - | - | 4166 |
| &nbsp;&nbsp;&nbsp;Change in unrealized losses on cash flow hedges |  | - | - |  | (542) | - | (542) |
| &nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | - | - | (8308) | (8308) |
| **Balance as of March 31, 2025** | **104892547** | **49** | **361924** | **(11198)** | **59** | **(222227)** | **128607** |

---

(\*) Excluding 359,375 Forfeiture Shares

**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements**

**VALENS SEMICONDUCTOR LTD.**

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(U.S. dollars in thousands)

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss for the period | (8290) | (8308) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Income and expense items not involving cash flows: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 618 | 770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 3136 | 4166 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange rate differences | 149 | 140 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized and unrealized loss (gain) on non-designated derivative instruments | 5 | (204) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest on short-term deposits | (327) | 517 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in earnout liability | (282) | 174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction in the carrying amount of ROU assets | 310 | 418 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings of investee, net of dividend received | (2) | (3) |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable | (509) | (1800) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 235 | 825 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (789) | (762) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (24) | (115) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | (69) | (1864) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 405 | (1620) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 637 | 288 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in operating lease liabilities | (379) | (230) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 44 | (3) |
| &nbsp;&nbsp;&nbsp;Net cash used in operating activities | (5132) | (7611) |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Investment in short-term deposits | (5664) | (30005) |
| &nbsp;&nbsp;&nbsp;Maturities of short-term deposits | 13565 | 53278 |
| &nbsp;&nbsp;&nbsp;Purchase of property and equipment | (437) | (357) |
| &nbsp;&nbsp;&nbsp;Derivative instruments of non-designated hedges | (5) | (265) |
| &nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 7459 | 22651 |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Repurchase of Ordinary Shares | - | (9585) |
| &nbsp;&nbsp;&nbsp;Earnout payment | (1962) | - |
| &nbsp;&nbsp;&nbsp;Exercise of stock options | 775 | 188 |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | (1187) | (9397) |
| **Effect of exchange rate changes on cash and cash equivalents** | (33) | (69) |
| **INCREASE IN CASH AND CASH EQUIVALENTS** | 1107 | 5574 |
| **CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD** | 27863 | 35423 |
| **CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD** | 28970 | 40997 |
| **SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:** |  |  |
| Trade accounts payable on account on property and equipment | 180 | 62 |
| Operating lease liabilities arising from obtaining operating right-of-use assets | 54 | 213 |

---

**The accompanying notes are an integral part of the unaudited condensed consolidated financial statements**

**VALENS SEMICONDUCTOR LTD.**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

**NOTE 1 - GENERAL:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**a.** Valens Semiconductor Ltd. (hereafter
 "Valens", and together with its wholly owned subsidiaries, the "Company"),
 was incorporated in Israel in 2006.

As of March 31, 2021, the Company began trading on the New York Stock Exchange under the Symbol "VLN".

Valens is a leading provider of semiconductor products (chips), operates in the Audio-Video, industrial, machine vision, medical (all referred to as the "CIB") and Automotive industries, renowned for its Physical Layer (PHY) technologies, enabling resilient high-speed connectivity over simple, low-cost infrastructure. Valens is the inventor of the HDBaseT Technology, which enables the converged delivery of ultra-high-definition digital video and audio, Ethernet, control signals, USB and power through a single cable. In the audio-video space, Valens' HDBaseT technology enables plug-and-play digital connectivity between ultra-HD video sources and remote displays. In the automotive domain, Valens' product offering includes both symmetric and asymmetric connectivity solutions for high bandwidth transmission of native interfaces over single low-cost wires and connectors. Valens' advanced PHY technologies for the auto industry provides the safety and resilience required to handle the noisy automotive environment, addressing the needs of Advanced driver-assistance systems (ADAS), Automotive Data Solutions (ADS), infotainment, telematics and backbone connectivity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**b.** On October 7, 2023, Hamas launched
 a series of attacks on civilian and military targets in Southern Israel and Central Israel,
 to which the Israel Defense Forces responded. In addition, Iran, Hezbollah and the Houthi
 movement attacked military and civilian targets in Israel, to which Israel responded, including
 through increased air and/or ground operations in Lebanon, Syria, Yemen and Iran. Following
 years of conflict in the region, on October 9, 2025, Israel, Hamas, the United States and
 other countries in the region agreed to a framework for a ceasefire in Gaza between Israel
 and Hamas. On February 28, 2026, the United States and Israel launched joint combat operations
 in Iran to which Iran and Hezbollah responded with ballistic missile and drone attacks on
 Israel as well as other countries and U.S. military bases in the region. On April 8, 2026,
 the United States and Iran agreed to a two-week ceasefire. How long and how severe the current
 conflicts in Gaza, Northern Israel, Lebanon, Iran or the broader region last and become is
 unknown at this time and any continued clash among Israel, Hamas, Hezbollah, Iran or other
 countries or militant groups in the region may escalate in the future into a greater regional
 conflict. The Company performs an ongoing assessment of the evolving situation and has assessed
 that currently there is no material impact of the current conflict on the Company's
 operations, financial position, or results of operations. The Company continues to assess
 potential impacts in light of changes and developments.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**a.** **Basis of Presentation** 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial reporting.

Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In our opinion, the information contained herein reflects all adjustments necessary for a fair statement of our results of operations, financial position, cash flows, and shareholders' equity. All such adjustments are of a normal, recurring nature.

**VALENS SEMICONDUCTOR LTD.**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (continued)**:**

The results of operations for the three months ended March 31, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements that were included in Form 20-F for the year ended December 31, 2025.

The carrying value of cash and cash equivalents, accounts receivables, deposits and accounts payable (included in the condensed consolidated balance sheets) approximates their fair value because of their generally short maturities.

There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**b.** **New Accounting Pronouncements** 

**Accounting pronouncements effective in future periods:**

In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business entity's expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative, and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential impact of this guidance on its consolidated financial statement disclosures.

In September 2025, the FASB issued Accounting Standards Update 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06"). ASU 2025-06 provides targeted improvements to the accounting for internal-use software costs by replacing the existing project-stage model with a principles-based approach to determine when capitalization of costs should begin. ASU 2025-06 is effective for all entities, on a prospective basis, for annual reporting periods beginning after December 15, 2027, including interim reporting periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2025-06 will have on its consolidated financial statements.

**VALENS SEMICONDUCTOR LTD.**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 3 - INVENTORIES:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31,<br> 2026** | **March 31,<br> 2026** | **December 31, 2025** | **December 31, 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Work in process |  | 6581 |  | 5008 |
| Finished goods | | 4,325 | | 5,109 |
|  | | **10,906** | | **10,117** |

---

Inventories write-downs amounted to $106 thousand and $0 thousand during the three months ended March 31, 2026, and 2025, respectively. Inventory write-downs are recorded in cost of revenues.

**NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**a.** **Noncancelable Purchase Obligations** 

The Company depends upon third party subcontractors for manufacturing of wafers, packaging and final tests. As of March 31, 2026, and December 31, 2025, the total value of open purchase orders acknowledged by such manufacturing contractors was approximately $9,443 thousand and $5,333 thousand, respectively.

The Company has noncancelable purchase agreements for certain IP embedded in the Company's products as well as certain agreement for the license of development tools used by the development team. As of March 31, 2026, and December 31, 2025, the total value of non-paid amounts related to such agreements totaled to $4,437 thousand and $5,015 thousand, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**b.** **Legal proceedings** 

As of March 31, 2026 and December 31, 2025, the Company is not a party to, or subject to the provisions of any order, writ, injunction, judgment or decree of any court or governmental agency or instrumentality. There is no material action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate.

On March 26, 2024, the Company received a complaint from a customer regarding allegedly damaged chips due to a certain batch production incident that customer embedded in its product. The company identified and remedied the production process.

On September 10, 2024, the customer sent a cost claim letter in the amount of 2,096 thousand Euro.

In 2024, the Company recorded a relevant provision in its books, within its other current liabilities. Relevant expenses were recorded in the general and administrative expenses.

In June 2025, following the ongoing discussions with the customer and updated indications, the Company decreased the provision in its financial statements by $323 thousand. The reversal of the provision was recorded in the general and administrative expenses.

In October 2025, the insurance company provided a draft release and discharge agreement to be signed by the Company, the customer, and the insurer. Subject to the final execution of such agreement by all parties, the insurance company will pay the customer $1,726 thousand, less a $250 thousand retention amount to be paid by the Company, as final settlement of the claim.

**VALENS SEMICONDUCTOR LTD.**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES** (continued):

Based on the progress achieved and the insurance company's written confirmation of its intent to settle, management determined that the realization of the reimbursement from the insurer is probable and the amount is reasonably estimable. Accordingly, the Company recognized in September 2025 an insurance recovery asset of $1,476 thousand (representing the expected reimbursement from the insurer). The related income was recognized within general and administrative expenses in the consolidated statement of operations.

In December 2025, following the draft release and discharge agreement, and the customer's feedback to this letter, the Company decreased the provision in its financial statements by additional $412 thousand. Reversal of the provision was recorded in the general and administrative expenses.

As of March 31, 2026, and December 31, 2025, the provision amounted to $1,726 thousand, while the insurance recovery asset amounted to $1,476 thousand. The remaining difference of $250 thousand reflects the retention amount to be paid by the Company.

**NOTE 5 - OTHER CURRENT LIABILITIES:**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Accrued vacation | 3898 | 3707 |
| Tax authority and other institutions | 215 | 347 |
| Estimated accrual for a certain batch production incident | 1726 | 1726 |
| Derivative liabilities | 80 | - |
| Accrued expenses | 1797 | 1274 |
| Revenue Earnout payables (please refer to Note 6) | - | 1962 |
| Other | 162 | 114 |
|  | **7878** | **9130** |

---

**NOTE 6 - EARNOUT LIABILITY**

During 2024 the Company acquired Acroname Inc., a US company specializing in advanced automation and control technologies. With respect to the Acroname's acquisition, the Company shall be obligated to pay Acroname's former shareholders earn out payments of up to $7.2 million, of which an amount of $1.5 million upon completion of a development of a certain product by June 2026, and the remaining amount depending on the achievement of certain revenue, EBITDA and cashflow targets in 2024 and 2025.

The Company recorded earn-out liability in connection with these payments at fair value on the acquisition date.

Each reporting period thereafter, the Company revaluated the earn-out liability and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.

Changes in the fair value of earnout liability can result from adjustments to the discount rates, revenues, profitability targets and achievement of mutual development project. This fair value measurement represents Level 3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining the assumptions utilized as of the acquisition date and for each subsequent period.

**VALENS SEMICONDUCTOR LTD.**

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 6 - EARNOUT LIABILITY** (continued):

As of December 31, 2025, after achieving the revenue, EBITDA and cash flow targets, the Company calculated the Revenues Earnout according to the actual revenues achieved during the period starting from the Closing date and until December 31, 2025. The Revenues Earnout, amounting to $1,962 thousand, was included in the other current liabilities as of December 31, 2025, and was paid in March 2026.

As of December 31, 2025, the Company calculated the Joint Product Earnout using the probability that the targets will be achieved, a discount rate of 13.22% and expected term of 0.5 years.

As of March 31, 2026, the Company estimated that these targets will not be achieved and therefore eliminated the Joint Product Earnout.

The following table summarizes the activity for the earnout liability, where fair value measurement is estimated utilizing Level 3 inputs:

---

| | | |
|:---|:---|:---|
|  | **Three months<br> ended<br> March 31,<br> 2026** | **Year ended<br> December 31, <br> 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Fair value at the beginning of the period | 282 | 2413 |
| Reclassification of Revenues Earnout to other current liabilities | - | (1962) |
| Change in fair value of earnout liability | (282) | (169) |
| Fair value at the end of the period | **-**  | **282** |

---

**NOTE 7 - DERIVATIVES AND HEDGING:**

**Derivatives**

Generally accepted accounting principles require all derivatives, whether designated in a hedging relationship or not, to be recorded on the balance sheet at fair value. These derivative instruments are measured at fair value within Level 2 of the fair value hierarchy. The Company's earnings and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. The Company's foreign currency risk management strategy is principally designed to mitigate the future potential financial impact of changes in the U.S. Dollar value of anticipated transactions and balances denominated in ILS resulting from changes in USD/ILS exchange rates. The Company entered into derivative transactions, specifically foreign currency forward contracts, to manage its exposure to foreign currency exchange risk to reduce earnings volatility. The Company does not enter into derivative transactions for trading or speculative purposes.

**Non-Designated Hedges**

The Company hedges its foreign currency monetary assets primarily resulting from foreign currency denominated short-term deposits with foreign exchange forward contracts to reduce the risk that the Company's earnings and cash flows will be adversely affected by changes in foreign currency exchange rates. These contracts have maturities of up to approximately 12 months. Generally, The Company does not designate these foreign currency forward contracts as hedges for accounting purposes and changes in the fair value of these instruments are recognized immediately in earnings. Any gains or losses on the underlying foreign-denominated balance are offset by the losses or gains on the forward contract. Derivative instruments are recorded as other current assets or other current liabilities.

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 7 - DERIVATIVES AND HEDGING** (continued):

As of March 31, 2026, the derivative instruments are recorded as other current liabilities. Gains and losses on forward contracts and foreign denominated deposits are included in financial income, net. The cash flows associated with these derivatives are classified in the consolidated statements of cash flows consistently with the classification of the underlying hedged transaction, within cash flows from investing activities.

As of March 31, 2026 and December 31, 2025, we had outstanding forward contracts not designated as hedging instruments with notional and fair value amounts equivalent to the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Currency Hedged** | **March 31,<br> 2026** | **March 31,<br> 2026** | **December 31, <br> 2025** | **December 31, <br> 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Israeli Shekel / U.S. Dollar |  | 846 |  | 311 |
| Fair value of derivatives assets |  | - |  | 2 |
| Fair value of derivatives liabilities |  | 6 |  | **-**  |

---

The following table shows the effect of our non-designated hedges on the Consolidated Statements of Operations for the Three months ended March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
|  | **Location of<br> Gain** | **Three months ended<br> March 31,** | **Three months ended<br> March 31,** |
|  |  | **2026** | **2025** |
|  |  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Net realized and unrealized gain (loss), excluding the underlying foreign currency exposure being hedged | &nbsp;&nbsp;Financial income, net | (5) | 204 |

---

For the three months ended March 31, 2026 and 2025, foreign currency profit, net was $0 and $183 thousand, respectively.

**Designated Hedges** 

During the fourth quarter of 2024 the Company initiated a foreign currency cash flow hedging program, designed to hedge the Company's foreign exchange rate risk, resulting from ILS payroll expenses. The Company hedges portions of its forecasted payroll payments denominated in ILS for a period of up to 12 months, using forward contracts that are designated as cash flow hedges, as defined by ASC 815. Derivative instruments are recorded as other current assets or other current liabilities, according to the timing of the cash flows. As of March 31, 2026, the derivative instruments are recorded as other current assets ($138 thousands) and other current liabilities ($80 thousands). For these derivative instruments, designated as a cash flow hedge, gains and losses are reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the hedged transaction and in the same period or periods during which the hedged transaction affects the statement of operations. As of March 31, 2026, the Company expects to reclassify all of its unrealized gains and losses from accumulated other comprehensive loss to earnings during the next twelve months. The cash flows associated with these derivatives are classified in the consolidated statements of cash flows consistently with the classification of the underlying hedged transaction, within cash flows from operating activities.

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 7 - DERIVATIVES AND HEDGING** (continued):

The notional and fair value amount and fair value of outstanding derivatives at the end of each period were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31,<br> 2026** | **March 31,<br> 2026** | **December 31,<br> 2025** | **December 31,<br> 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Notional amount of foreign currency contracts |  | 14917 |  | 10921 |
| Fair value of foreign currency contracts |  | 65 |  | 429 |

---

The change in accumulated other comprehensive income relating to gains or losses on derivatives used for hedging was as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31,** | **Three months ended<br> March 31,** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Other comprehensive income (loss) before reclassifications | 118 | (355) |
| Amounts reclassified out of accumulated other comprehensive income (\*) | (482) | (187) |
| Other comprehensive loss, net | (364) | (542) |

---

(\*) Amounts of gains reclassified from other comprehensive loss into profit or loss are recorded in cost of revenue and operating expenses. In the three months ended March 31, 2026, $14 thousand, $279 thousand, $101 thousand and $87 thousand were recorded in cost of revenue, research and development, sales and marketing and general and administrative expenses, respectively. In the three months ended March 31, 2025, $5 thousand, $119 thousand, $37 thousand and $26 thousand were recorded in cost of revenue, research and development, sales and marketing and general and administrative expenses, respectively.

**NOTE 8 - TREASURY SHARES**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. On December 27, 2024, the Company initiated a share repurchase
program (the – "Buyback"), at an aggregate amount of up to $10 million. During 2024 and 2025, the Company has repurchased
in the open market a total of 3,302,194 shares at a total consideration of $10 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. On February 11, 2025, the Company initiated a second share
repurchase program (the – "Second Buyback"), at an aggregate amount of up to $15 million. During 2025, The Company
has repurchased in the open market a total of 6,151,225 shares at a total consideration of $15 million.

Overall, in the framework of the Buyback and the Second Buyback, the Company repurchased a total amount of 9,453,419 Ordinary Shares, for a total amount of $25 million.

During 2025, 6,151,225 shares were formally cancelled and retired from the Company's issued share registration. On January 22, 2026, 3,302,194 shares were formally cancelled and retired from the Company's issued share registration.

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 9 - STOCK-BASED COMPENSATION**:

**Stock Options**

As of March 31, 2026, and December 31, 2025, the number of ordinary shares included in the Company's option plans totaled to 49,893,452 and 44,740,618, respectively.

5,372,834 out of the outstanding options that have not yet vested as of March 31, 2026, have acceleration mechanisms according to certain terms set forth in the grant agreements primarily in the case of an M&A Transaction which constitutes a Liquidation Event.

As of March 31, 2026, the unrecognized compensation costs related to those unvested stock options are $3,441 thousand, which are expected to be recognized over a weighted-average period of 2.32 years.

The following is a summary of the status of the Company's share option plan as of March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Three months ended** | **Three months ended** |
|  | **March 31, 2026** | **March 31, 2026** |
|  | **Number of Options** | **Weighted-Average Exercise price** |
| Options outstanding as of December 31, 2025 | 15857856 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.81 |
| Granted during the period | 397628 | $1.66 |
| Exercised during the period | (933422) | $0.83 |
| Forfeited during the period | (176644) | $2.59 |
| Options outstanding as of March 31, 2026 | 15145418 | $1.86 |
| Options exercisable as of March 31, 2026 | 8214606 | $1.12 |

---

The following table summarizes information about stock options outstanding as of March 31, 2026:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Outstanding as of March 31, 2026** | **Outstanding as of March 31, 2026** | **Outstanding as of March 31, 2026** | **Outstanding as of March 31, 2026** | **Outstanding as of March 31, 2026** | **Exercisable as of March 31, 2026** | **Exercisable as of March 31, 2026** | **Exercisable as of March 31, 2026** | **Exercisable as of March 31, 2026** |
| **Range of exercise prices** | **Number outstanding** | **Weighted average remaining contractual term** | **Weighted average exercise price** | **Aggregate intrinsic value (U.S. dollars in thousands)** | **Number Exercisable** | **Weighted average remaining contractual term** | **Weighted Average exercise price** | **Aggregate intrinsic value (U.S. dollars in thousands)** |
| $0.15-$0.86 | 7304858 | 3.25 | 0.82 | 2284 | 7301513 | 3.25 | 0.82 | 2284 |
| $1.66-$1.87 | 400941 | 6.78 | 1.66 | - | 3313 | 4.78 | 1.87 |  |
| $2.00-$2.13 | 2405710 | 6.69 | 2.00 | - | 27855 | 5.50 | 2.13 |  |
| $2.27 | 1224460 | 6.25 | 2.27 | - | 7827 | 6.43 | 2.27 |  |
| $2.39-$2.41 | 740827 | 5.34 | 2.40 | - | 542038 | 5.28 | 2.40 | - |
| $3.25 | 1350000 | 6.71 | 3.25 | - |  |  |  | - |
| $4.25 | 1350000 | 6.71 | 4.25 | - |  |  |  | - |
| $4.99 | 168165 | 3.50 | 4.60 | - | 140353 | 3.61 | 4.74 | - |
| $5.36 | 140000 | 3.25 | 5.36 | - | 131250 | 3.25 | 5.36 |  |
| $7.58 | 56920 | 2.80 | 7.58 | - | 56920 | 2.80 | 7.58 |  |
| $9.07 | 3537 | 2.71 | 9.07 | - | 3537 | 2.71 | 9.07 |  |

---

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 9 - STOCK-BASED COMPENSATION** (continued):

The calculated fair value of option grants was estimated using the Black-Scholes option-pricing model with the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **For the three months ended on <br>March 31,<br>2026** | **For the<br>three months<br>ended on<br>March 31,<br>2025** |
| Expected term | 4 | 4-5 |
| Expected volatility | 68.19% | 59.63%-63.35% |
| Expected dividend rate | 0% | 0% |
| Risk-free rate | 3.65% | 4.34%-4.36% |

---

During the three-month period ended on March 31, 2026, 397,628 options were granted to related parties (please refer to Note 14 for further information).

As of March 31, 2026, the unrecognized compensation costs related to unvested stock options was $4,405 thousand, which are expected to be recognized over a weighted-average period of 3.09 years.

The weighted-average fair value of the options that were granted during the period ended March 31, 2026, was $1.66 at the grant date.

The total intrinsic value of options exercised during the period of three months ended March 31, 2026 was $693 thousand.

The following table presents the classification of the stock options expenses for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **Three months Ended March 31** | **Three months Ended March 31** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Cost of revenue | 20 | 27 |
| Research and development | 41 | 135 |
| Sales and marketing | 43 | 58 |
| General and administrative | 408 | 163 |
| **Total stock-based compensation** | **512** | **383** |

---

**Restricted Stock Units**

The following is a summary of the status of the Company's RSU's as of March 31, 2026, as well as changes during the period of three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Number of RSUs** | **Weighted-Average Grant Date Fair Value** |
| RSUs outstanding at the beginning of the year | 8602317 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.95 |
| Granted during the period | 4153811 | $1.32 |
| Vested during the period | (1738725) | $3.35 |
| Forfeited during the period | (417140) | $2.84 |
| Outstanding at the end of the period | 10600263 | $2.25 |

---

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 9 - STOCK-BASED COMPENSATION** (continued):

As of March 31, 2026, the unrecognized compensation cost related to unvested RSUs totaled to approximately $20,932 thousand and is expected to be expensed over a weighted-average recognition period of approximately 2.63 years.

During the three-month period ended on March 31, 2026, 688,929 RSU's were granted to several related parties (please refer to Note 14 regarding Related Parties).

The following table presents the classification of RSU's expenses for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31,** | **Three months ended<br> March 31,** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Cost of revenue | 184 | 223 |
| Research and development | 1266 | 1736 |
| Sales and marketing | 640 | 1169 |
| General and administrative | 534 | 655 |
| **Total stock-based compensation-RSUs** | **2624** | **3783** |

---

**NOTE 10 - NET LOSS PER ORDINARY SHARE:**

The following table sets forth the computation of basic and diluted net loss per Ordinary Share for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **Three months ended** <br> **March 31** | **Three months ended** <br> **March 31** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| **Basic net loss per ordinary share** |  |  |
| Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | (8290) | (8308) |
| Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;Weighted average common shares and vested RSUs – basic and diluted | 105047377 | 105255959 |
| Basic and dilutive net loss per common share | (0.08) | (0.08) |

---

The following weighted-average Ordinary Shares of securities and vested RSU's were not included in the computation of diluted net loss per common share as their effect would have been antidilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2026** | **2025** | **2025** |
| Options |  | 12055075 |  | 10693595 |
| Unvested Restricted Stock Units |  | 9198084 |  | 10281304 |
| Private Warrants |  | 3330000 |  | 3330000 |
| Public Warrants |  | 5750000 |  | 5750000 |
| Forfeiture Shares |  | - |  | 359375 |

---

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 11 - FINANCIAL INCOME, NET**

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Foreign currency exchange differences | (149) | (140) |
| Realized and unrealized losses on derivative instruments | (5) | 204 |
| Interest income on short-term deposits | 839 | 1234 |
| Other | (12) | (60) |
| **Total financial income, net** | **673** | **1238** |

---

**NOTE 12 - SEGMENT AND REVENUE BY GEOGRAPHY AND BY MAJOR CUSTOMER**:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**a.** The chief operating decision maker (the "CODM")
is the Company's Chief Executive Officer , who makes resource allocation decisions and assesses performance based on financial information
prepared on a consolidated basis, accompanied by disaggregated information about revenues, gross profit and operating loss by the two
identified reportable segments. The Company's business includes two operating segments based on the two markets the Company serves:

Cross Industry Business: The Company's solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable.

Automotive: Valens Automotive delivers safe & resilient high-speed in-vehicle connectivity for advanced car architectures, realizing the vision of connected and autonomous cars.

For the purpose of evaluating financial performance and allocating resources, the CODM reviews financial information presented on a consolidated basis accompanied by disaggregated information about revenues, gross profit and operating loss by the two identified reportable segments, to make decisions about resources to be allocated to the segments and assess their performance. Assets information is not provided to the CODM and is not reviewed. Revenues and cost of goods sold are directly associated with the activities of a specific segment. Direct operating expenses, including general and administrative expenses, associated with the activities of a specific segment are charged to that segment. General and administrative expenses which cannot be attributed directly, are allocated evenly between segments. Other operating expenses are allocated to segments based on headcount ratio.

The CODM monitors the gross profit of each segment to analyze fluctuations relative to prior periods (cost reductions, change in product mix etc.).

The CODM uses segment operating profit (loss) to evaluate income (loss) in deciding whether to reinvest profits into the segment. Segment operating profit (loss) is used to monitor budget versus actual results, in order to assess the performance of the segment.

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 12 - SEGMENT AND REVENUE BY GEOGRAPHY AND BY MAJOR CUSTOMER** (continued):

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended on March 31, 2026** | **Three months ended on March 31, 2026** | **Three months ended on March 31, 2026** |
|  | **CIB** | **Automotive** | **Consolidated** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Revenues | 10983 | 5876 | 16859 |
| Cost of revenues | (3209) | (3163) | (6372) |
| Gross profit | 7774 | 2713 | 10487 |
| Research and development expenses | 7067 | 3227 | 10294 |
| Sales and marketing expenses | 3113 | 2283 | 5396 |
| General and administrative expenses | 2161 | 1856 | 4017 |
| Change in earnout liability | (282) | - | (282) |
| Segment operating loss | (4285) | (4653) | (8938) |
| Financial income, net |  |  | 673 |
| Loss before taxes on income |  |  | (8265) |
| Depreciation and Amortization expenses | 434 | 184 | 618 |
| Stock-based compensation | 1706 | 1430 | 3136 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended on March 31, 2025** | **Three months ended on March 31, 2025** | **Three months ended on March 31, 2025** |
|  | **CIB** | **Automotive** | **Consolidated** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Revenues | 11753 | 5075 | 16828 |
| Cost of revenues | (3629) | (2617) | (6246) |
| Gross profit | 8124 | 2458 | 10582 |
| Research and development expenses | 6653 | 3937 | 10590 |
| Sales and marketing expenses | 2791 | 2816 | 5607 |
| General and administrative expenses | 2029 | 1638 | 3667 |
| Change in earnout liability | 174 | - | 174 |
| Segment operating loss | (3523) | (5933) | (9456) |
| Financial income, net |  |  | 1238 |
| Loss before taxes on income |  |  | (8218) |
| Depreciation and Amortization expenses | 537 | 233 | 770 |
| Stock-based compensation | 1875 | 2291 | 4166 |

---

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 12 - SEGMENT AND REVENUE BY GEOGRAPHY AND BY MAJOR CUSTOMER** (continued):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**b.** **Geographic Revenues** 

The following table shows revenue by geography, based on the customers' "bill to" location:

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Domestic (Israel) | 78 | 64 |
| Hungary | 2875 | 2880 |
| United States | 2436 | 2686 |
| Portugal | 2876 | 2237 |
| China | 1033 | 2221 |
| Hong Kong | 1062 | 1815 |
| Other | 6499 | 4925 |
|  | **16859** | **16828** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**c.** **Supplemental data - Major Customers**:

The following tables summarize the significant customers' (including distributors) accounts receivable and revenues as a percentage of total accounts receivable and total revenues, respectively:

---

| | | |
|:---|:---|:---|
| | **March 31,<br> 2026** | **December 31,<br> 2025** |
| <br>**Accounts Receivable** | **% of Account Receivable** | **% of Account Receivable** |
| Customer A | &nbsp;&nbsp;&nbsp;&nbsp; 26% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16% |
| Customer B | 12% | 15% |
| Customer C | 5% | 15% |
| Customer D | 14% | 10% |
| Customer E | 0% | 10% |

---

---

| | | |
|:---|:---|:---|
|  | **Three months ended<br> March 31** | **Three months ended<br> March 31** |
|  | **2026** | **2025** |
|  | **% of Revenues** | **% of Revenues** |
| **Revenues** |  |  |
| Customer A | 15% | 13% |
| Customer D | 11% | 11% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**d.** **Long-lived assets by Geography:** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31,<br> 2026** | **March 31,<br> 2026** | **December 31,<br> 2025** | **December 31,<br> 2025** |
|  | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** | **U.S. dollars in thousands** |
| Domestic (Israel) |  | 8207 |  | 8657 |
| China |  | 137 |  | 138 |
| USA |  | 973 |  | 871 |
| Other | | 104 | | 136 |
|  | | **9,421** | | **9,802** |

---

**VALENS SEMICONDUCTOR LTD.** NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

(continued)

**NOTE 13 - RELATED PARTY TRANSACTIONS**

During the three months ended on March 31, 2026, the Company granted 397,628 stock options at a weighted average exercise price of $1.66 to several executive officers, and Board of Directors ("Board") members of the Company.

In addition, during the three months ended March 31, 2026, the Company granted 688,929 RSUs to several executive officers and Board members of the Company.

The fair value of the stock options that were granted during the three months ended March 31, 2026, is $485 thousand, which is expected to be recognized over a 1-4-year vesting period, and the fair value of the granted RSUs is $1,210 thousand, which is expected to be recognized over a 1-4-years vesting period.

![](ea029011501_ex99-1img1.jpg)